60 results about "Osteopontin" patented technology

The invention provides a composition for promoting bone health and bone formation as well as application and a product thereof, and belongs to the field of foods. The composition disclosed by the invention is prepared from the following components in parts by weight: 1 to 5 parts of osteopontin, 1 to 50 parts of 2 '-fucosyllactose and 0.05 to 50 parts of a calcium source. The composition disclosed by the invention shows a relatively good synergistic effect in promoting calcium absorption, and can be used for improving bone density, preventing and treating osteoporosis and the like.

The invention provides a nutrition enhancer beneficial to bone health of middle-aged and elderly people, a preparation method of the nutrition enhancer and application of the nutrition enhancer in preparation of medial care food, and belongs to the field of nutritious food. The nutrient supplement comprises a plant fermentation product, osteopontin peptide, collagen peptide, N-acetylglucosamine and calcium, vitamins and mineral substances can be added, and the plant fermentation product is obtained by performing anaerobic fermentation on rhizoma drynariae and chestnuts through a complex microbial inoculant composed of lactobacillus reuteri and bifidobacterium longum subsp. Longum; the collagen peptide is prepared by performing enzymolysis on bovine bones through alkaline protease and flavourzyme; the hydrogel is prepared by adopting a sodium alginate-calcium chloride-carboxymethyl chitosan micro-capsule embedding process. An in-vitro experiment shows that the nutrition enhancer can remarkably promote osteoblast proliferation, differentiation and mineralization; animal experiments show that the bone mineral density of osteoporosis model mice can be effectively improved. The nutrition enhancer disclosed by the invention is suitable for preparing care food and bone health products, and has a remarkable effect of improving bone health of middle-aged and elderly people.

The invention discloses goat milk with hypoglycemic activity and a preparation method thereof, and belongs to the technical field of enzyme engineering. The goat milk is used as a raw material, enzymolysis goat milk with alpha-G inhibitory activity is obtained through compound protease hydrolysis, it is found that the enzymolysis goat milk has hypoglycemic activity, and the goat milk powder with the hypoglycemic activity is further prepared through spray drying. The alpha-G inhibitory peptides in the enzymolysis goat milk are separated and identified, 20 alpha-G inhibitory peptides are found from components with the highest alpha-G inhibition rate, the molecular weight of the alpha-G inhibitory peptides is 377-962 Da, and the alpha-G inhibitory peptides are mainly derived from beta-casein, alpha S1-casein, alpha S2-casein, kappa-casein, beta-lactoglobulin, lactoglobulin and osteopontin of the goat milk. The alpha-G inhibitory peptide is prepared by hydrolyzing the goat milk through the compound enzyme, the amino acid sequence of the alpha-G inhibitory peptide is separated and identified, the goat milk with hypoglycemic activity is developed, and theoretical basis and technical support are provided for subsequent development of hypoglycemic dairy products.

The invention provides infant formula milk powder for improving intestinal inflammation and recovering key flora as well as a preparation method and application of the infant formula milk powder. The invention firstly provides the infant formula milk powder, the infant formula milk powder comprises 2 '-fucosyllactose and osteopontin, the mass ratio of the 2'-fucosyllactose to the osteopontin is 1: (0.017-1.3), and every 100 g of the infant formula milk powder comprises 8-24 g of protein, 14-31 g of fat, 0.83-7.6 g of dietary fiber and 50-61 g of carbohydrate. The infant formula milk powder can improve intestinal inflammation and recover key flora.

The application discloses a composition for improving bone density and application thereof, and belongs to the technical field of food. The composition is prepared by using 1,3-dioleic acid-2-palmitic acid triglyceride, osteonectin and oligosaccharide in combination, and through the interaction between the components, the absorption and utilization of each other are promoted, the growth and development of the bone of an infant in the growth period are improved, the bone mineral content and bone density are improved, the bone health is promoted, and the composition is safe and has no side effect. Through optimization of the types of the oligosaccharide, it is found that the combination of oligogalactose and 2'-fucosyllactose can better improve the growth and development of the bone of the infant in the growth period.

The invention belongs to the technical field of pharmaceutical compositions, and particularly relates to a composition helpful for improving bone mineral density and application thereof. The composition comprises sheep milk casein peptide, collagen tripeptide, sea cucumber peptide and osteopontin, can achieve the effects of improving bone mineral density and preventing and treating osteoporosis, integrates functionality and nutrition, and has wide application prospects in the aspect of promoting calcium absorption.

The invention discloses a preparation technology of a lactoferrin and osteopontin compound capable of improving bone health, and belongs to the technical field of food processing. In the compound, the mass ratio of lactoferrin to osteopontin is (3-5): 1, and the pH is 4-5.5. In a zebra fish model, after intervention of the lactoferrin, the osteopontin, the compound or the mixture, compared with a mixture group, the compound group of the lactoferrin and the osteopontin can obviously improve the fluorescence intensity of zebra fish spines, the relative bone mineral density is improved by 31.12%, and compared with a blank group, the relative bone mineral density is improved by 2.39 times. Therefore, the lactoferrin and osteopontin compound with the function of improving bone health can be prepared, and the lactoferrin and osteopontin compound has good application potential.

The present invention discloses an inducer, macrophages, and their applications, relating to the interdisciplinary fields of immunology, cell biology, and regenerative medicine. The invention utilizes a composition composed of osteopontin (OPN) and other cytokines to culture and induce monocytes, thereby generating macrophages with strong repair functions. These macrophages can be used to repair tissue wounds, promoting the healing and tissue regeneration of chronic, difficult-to-heal wounds, and exhibiting excellent repair effects, making them suitable for widespread application.

The invention relates to the technical field of biology, in particular to application of osteopontin in regulation of intestinal anaerobic symbiotic bacteria colonization. The osteopontin is used for preparing food or medicine for improving the immunity of the intestinal tract, and the food or medicine is used for improving the abundance of anaerobic symbiotic bacteria in the intestinal tract; according to the application disclosed by the invention, firstly, by virtue of transcriptome analysis, it is proved that the abundance of Parabacteroids distans and Blautiapseudococcoids can be remarkably improved by virtue of the exogenous osteopontin, so that the abundance of the Parabacteroids distans and the abundance of the Blautiapseudococcoids can be remarkably improved; secondly, the invention also proves that the exogenous osteopontin can be used for inhibiting the proliferation of harmful bacteria Escherichia coli; therefore, the intestinal immunity is improved, the intestinal barrier is improved or repaired, and the intestinal flora balance is maintained. The composition is suitable for infants, old people, patients and other people with low immunity.

The invention discloses an application of a protein substance in preparation of a composition for inhibiting coronavirus. The coronavirus inhibition comprises the following steps: inhibiting adhesion of the coronavirus on host cells; the invasion of coronavirus to host cells is hindered; the after-cell entry process of coronavirus infection is inhibited. In-vitro verification is carried out on the antiviral effect of the coronavirus GXP2V on various nutritional ingredients (whey protein, milk fat globule membrane, lactoferrin and milk-derived osteopontin), and the result shows that the coronavirus resisting activity of the whey protein, the milk fat globule membrane, the lactoferrin and the milk-derived osteopontin (LPN, short for lactopontin). At present, it is rarely reported that protein substances are used for resisting the coronavirus, the coronavirus GXP2V is a novel coronavirus-like virus, a new thought is developed for resisting the novel coronavirus-like virus, and the application value and prospect are very good.

An antisense oligonucleotide (ASO) that is capable of binding to a target sequence in a mRNA of a secreted phosphoprotein 1 (SPP1) or osteopontin (OPN) gene, the mRNA having a start codon in an open reading frame encoding the SPP1 or OPN, and the target sequence including the start codon in the open reading frame of the mRNA. Binding of the ASO to the target sequence disrupts translation of the ORF encoding the SPP1 or OPN. Alternatively, an ASO wherein the ASO is capable of binding to a target sequence in a pre-mRNA of a SPP1 or OPN gene. Also double-stranded DNA or RNA molecules capable of binding to a target sequence in a mRNA or pre-mRNA of a SPP1 or OPN gene. Additionally, pharmaceutical compositions and methods of treatments using the ASOs or double-stranded DNA or RNA molecules.

The present invention relates to the use of urine protein as a diagnostic marker for primary biliary cholangitis (PBC). The urine protein includes one or a combination of osteopontin (OPN), receptor activity-modifying protein 3 (RAMP3), and calcium-binding protein (S100A8). This application uses urine as a non-invasive test sample, making it more readily accepted by patients than blood. It is of great significance for the early, non-invasive diagnosis of PBC patients.

Disclosed is a method for diagnosing or predicting a stage of colorectal health status in an individual, including: providing a biological fluid sample of the individual; detecting the content of a marker in the biological fluid sample; and determining the stage of the colorectal health status in the individual according to the detected content of the marker, where the biomarker is selected from: any one or more of trefoil factor 1, trefoil factor 3, insulin-like growth factor binding protein 1, insulin-like growth factor binding protein 4, serine protease inhibitor A1, osteopontin, or growth differentiation factor-15.

Therapeutic antibodies specific for osteopontin and methods of using them for treating osteopontin-associated disorders are provided. In particular, antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin are provided. Additionally, antibody conjugates and pharmaceutical compositions or formulations comprising the antibodies or antibody conjugates as well as kits including the antibodies, conjugates, or formulations are also provided.

Compositions and methods for detection of anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) patients. Patient samples known or suspected of containing ACPAs were probed against citrullinated proteins, and antibody responses to 190 citrullinated proteins in 20 RA patients were investigated. Unique antibody reactivity patterns in both clinical anti-cyclic citrullinated peptide assay positive (CCP+) and negative (CCP−) RA patients were observed. At individual antigen levels, six novel antibody / antigen complexes were discovered and validated against specific citrullinated antigens (Myelin Basic Protein (MBP), osteopontin (SPP1), flap endonuclease (FEN1), insulin like growth factor binding protein 6 (IGFBP6), insulin like growth factor I (IGF1) and stanniocalcin-2 (STC2)) in RA patients. Identification of immune-dominant epitope(s) for citrullinated MBP was also performed. The identified biomarkers have high specificity, especially MBP.

The application provides a composition for promoting bone health and bone formation, and application and products thereof, and belongs to the field of food. The composition of the application is composed of 2'-fucosyllactose, osteopontin and a calcium source, wherein the osteopontin is 1-5 parts, the 2'-fucosyllactose is 1-50 parts and the calcium source is 0.05-50 parts by weight. The composition of the application shows a good synergistic effect in promoting calcium absorption, and can be used for increasing bone density, preventing and treating osteoporosis and the like.

The invention provides a children formula food for improving intestinal inflammation and recovering key flora as well as a preparation method and application of the children formula food. The invention firstly provides the infant formula food, the infant formula food is infant formula food or children formula food, the infant formula food comprises 2 '-fucosyllactose and osteopontin, and the mass ratio of the 2'-fucosyllactose to the osteopontin is 1: (0.017-1.3). The children formula food disclosed by the invention can improve intestinal inflammation and recover key flora.

Therapeutic antibodies specific for osteopontin and methods of using them for treating osteopontin-associated disorders are provided. In particular, antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin are provided. Additionally, antibody conjugates and pharmaceutical compositions or formulations comprising the antibodies or antibody conjugates as well as kits including the antibodies, conjugates, or formulations are also provided.

The present invention relates to a combination comprising osteopontin and lactoferrin in effective amount for use in promoting social-emotional development in a young individual. The present invention further relates to compositions and methods for promoting social-emotional development in a young individual, preferably in an infant.

The present invention relates to compositions comprising osteopontin (OPN) for the treatment and / or prevention of viral infections in mammals, such as humans, in particular infants, young children and pre-schoolers.

This invention relates to a combination comprising effective amounts of osteopontin and lactoferrin, for use in promoting the socio-emotional development of young individuals. The invention also relates to compositions and methods for promoting the socio-emotional development of young individuals, preferably infants.

The invention provides application of a milk-derived active component in preparation of an orthopoxvirus inhibitor. The milk-derived active component comprises one or more of lactoferrin, whey protein, milk fat globule membrane and osteopontin. The milk-derived active component has the activity of remarkably inhibiting orthopox virus infection, and is a potential preparation for treating monkey pox and vaccinia virus infectious diseases. The lactoferrin can inhibit virus infection in the whole life cycle of the virus, has important medicinal value, and is a promising candidate preparation for treating infectious diseases of monkey pox virus and other orthopox virus.

The present application provides a method and an apparatus for preparing humanized infant formula milk powder and functional milk powder. The method includes: separating liquid raw milk, calculating and determining a mixing ratio based on the component substance content in the separated fluid to make it humanized or functionalized, and remixing and drying into powder at least one of de-β-lactoglobulin and zero-sugar milk protein fluid, β-lactoglobulin fluid, milk fat globule membrane protein fluid, antibacterial protein fluid, ribonuclease-osteopontin fluid, lactose fluid, sialic acid-lactose fluid, galactooligosaccharide-sialic acid fluid, mineral salt fluid, α-lactalbumin fluid, casein fluid, α-casein fluid, β-casein fluid, and liquid raw milk. This method can maximize the retention of the biological functional activities of various components, each fluid can be directly used for preparing milk powder without excessive processing, a formula calculation model is used to determine the mixing ratio of each fluid component, and milk powder can be made by one-time spray drying.

The present invention relates to a complex coacervate comprising lactoferrin and osteopontin, processes of producing the same and composition comprising the same. Moreover, the present invention relates to complexes comprising lactoferrin and osteopontin in the treatment and / or prevention of metabolic diseases and / or inflammatory diseases. Moreover, the present invention relates to complexes comprising lactoferrin and osteopontin for promoting bone development, growth, strength and / or healing, or preventing and / or treating a bone disease.

The invention discloses an application of a protein substance in preparation of a composition for inhibiting coronavirus. The coronavirus inhibition comprises the following steps: inhibiting adhesion of the coronavirus on host cells; the invasion of coronavirus to host cells is hindered; the after-cell entry process of coronavirus infection is inhibited. In-vitro verification is carried out on the antiviral effect of the coronavirus GXP2V on various nutritional ingredients (whey protein, milk fat globule membrane, lactoferrin and milk-derived osteopontin), and the result shows that the coronavirus resisting activity of the whey protein, the milk fat globule membrane, the lactoferrin and the milk-derived osteopontin (LPN, short for lactopontin). At present, it is rarely reported that protein substances are used for resisting the coronavirus, the coronavirus GXP2V is a novel coronavirus-like virus, a new thought is developed for resisting the novel coronavirus-like virus, and the application value and prospect are very good.

This invention relates to the field of food processing technology, and more particularly to a method and application for separating bovine colostrum whey. The method for separating bovine colostrum whey provided by this invention includes: mixing and adjusting bovine colostrum collected at different time points within 72 hours of calving to a raw milk with a total solids content of 14-20%; the raw milk is then defatted and enzymatically hydrolyzed to separate the whey; wherein the defatting temperature is 35-50℃. The method provided by this invention can efficiently separate and prepare bovine colostrum whey, with a whey extraction rate ≥70%. The obtained bovine colostrum whey has a high content of various active proteins. The obtained bovine colostrum whey can be used to prepare functional raw materials such as immunoglobulins, lactoferrin, and osteopontin.

Disclosed herein are methods of treatment for diseases and disorders with modulators of full-length or thrombin-cleaved osteopontin. Particularly disclosed herein are methods comprising treatment of tissue fibrosis (e.g., pulmonary, cardiac, liver, kidney, skin) with antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin.

The application discloses application of a composition in preparation of a product for improving constipation, and belongs to the technical field of food. The application adopts OPO, osteopontin and specific oligosaccharides in combination, promotes absorption and utilization of functional components such as minerals and fatty acids through interaction between the components, improves constipation of infants, regulates basal energy intake and intestinal health, and promotes growth and development of the infants.

The present invention relates to a nutritional composition comprising osteopontin as an active ingredient for use in promoting emotional development in a young individual, preferably in an infant. The present invention further relates to uses and methods for promoting emotional development in a young individual, preferably in an infant.

Provided is a method of mineralizing tissue, including placing within a body of a subject a substance, wherein the substance includes osteopontin and osteocalcin. Also provided is a tissue mineralization-promoting substance including osteopontin and osteocalcin, and an article for promoting tissue mineralization, including an implant which may be an orthopedic implant or an endosseous implant, and a substance disposed on a surface of the implant including osteopontin, and osteocalcin. A method of making a tissue mineralization-promoting substance, including combining osteopontin and osteocalcin, is also provided. Other features, including calcium phosphate, type-I collagen, mesenchymal stem cells, and growth factors, are also provided.